MultiCell Technologies, Inc., is a leading provider of liver cell-based products for drug discovery and therapeutic applications. The Company specializes in innovative cell immortalization technologies that lead to the reproducible creation of highly functional cell lines.

BrainStorm (OTC BB: BCLI) is a company that is developing stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. The Company is focused on developing adult stem cells taken from the patient's own bone marrow to treat diseases such as Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease), and Spinal Cord Injury.

Endovasc’s licenses and patents describe technological advancements related to liposomes, stent coatings, and biodegradable/resorbable prostheses (stents) for the treatment of vascular dysfunction and heart disease. It also holds licenses and patents for the treatment of vascular dysfunction related to heart disease.

HemaCare collects, processes and distributes human blood products to hospitals and research-related organizations. We operate donor centers and mobile donor vehicles to collect transfusable blood products from donors, and offer human-derived blood products to health research organizations. HemaCare also provides blood related services, principally therapeutic apheresis procedures, stem cell collection and other blood treatments, to patients and in connection with clinical trials.

International Stem Cell Corporation (ISCO) is the creator and developer of a new class of stem cells that addresses two of the greatest barriers to the therapeutic use of stem cells: Immune rejection and the ethical issues that surround the use of embryonic stem cells. ISCO makes its cells available to qualified researchers worldwide. Its technology, called “Parthenogenesis,” results in the creation of cell lines that may allow cells to be immune-matched to hundreds of millions of people without destroying a viable human embryo. ISCO also generates income through the sale of human primary cells and stem cell products through Lifeline Cell Technology, a wholly owned subsidiary of ISCO. For more information please visit our website at www.internationalstemcell.com, or E-mail info@IntlStemCell.com

Stem Cell Innovations is a publicly-traded (SCLL.OB) cell biology company. The company is well positioned to become a leader in the development of next generation drug discovery solutions including human cellular disease models and cell-based therapies. SCI's proprietary stem cell platform named PluriCells (TM) is capable of generating a broad range of differentiated human cell types.